GG2020 logo

Τhe HVP Global Globin 2020 Challenge is organising a fringe meeting at the 14th International Conference on Thalassaemia and Other Haemoglobinopathies. The meeting, entitled "Towards Comprehensive Global Epidemiology and Prevention of Haemoglobinopathies", will be held on 19th November 2017 at the Grand Hotel Palace – Ilida Meeting Room, Thessaloniki, Greece, between 14:00 and 16:30. 

The GG2020 Challenge  seeks to apply recent developments in human genomics, including the systematic collection and sharing of variation data, to fighting haemoglobinopathies (notably thalassaemias and sickle cell disease) in low- and middle-income countries. The GG2020 meeting, a great opportunity to forge new collaborations, will highlight the main goals and partnerships (including with WHO and UNESCO) of the Challenge and will provide an update on past achievements, ongoing projects and future plans. 

More information: Programme

 

Monday, 13 November 2017 14:50

ITHANET pre-print online

ITHANET logo trans300bioRxiv logo

 

We are pleased to inform you that a preprint describing all sections of the ITHANET portal is now available online on bioRxiv (doi: https://doi.org/10.1101/209361). This is the first article resulting from our partnership with the HVP Global Globin 2020 Challenge. Most importantly, we would like to thank everyone who supported the ITHANET portal, contributed data and provided suggestions for its improvement. 

Abstract

Haemoglobinopathies are the commonest monogenic diseases, with millions of carriers and patients worldwide. Online resources for haemoglobinopathies are largely divided into specialised sites catering for patients, researchers and clinicians separately. However, the severity, ubiquity and surprising genetic complexity of the haemoglobinopathies call for an integrated website to serve as a free and comprehensive repository and tool for patients, scientists and health professionals alike. This paper presents the ITHANET community portal, an expanding resource for clinicians and researchers dealing with haemoglobinopathies. It integrates information on news, events, publications, clinical trials and haemoglobinopathy-related organisations and experts and, most importantly, databases of variations, epidemiology and diagnostic and clinical data. Specifically, ITHANET provides annotation for 2690 haemoglobinopathy-related variations, epidemiological data for more than 180 countries and information for more than 600 HPLC diagnostic reports. The ITHANET portal accepts and incorporates contributions to its content by local experts from any country in the world and is freely available for the public at http://www.ithanet.eu.

CooleySAnemia

The Cooley's Anemia Foundation (CAF) sponsors incentive awards for thalassaemia patients to further their education and career goals and to help them live positively with thalassaemia. Applicants must be U.S. residents who are currently pursuing education in a graduate, undergraduate, associate, certificate or vocational level.

The incentive awards are given as follows:

·$2,000 for Doctorate programmes with the possibility of receiving two awards during the course of study.

·$1,500 for Master degree programmes with the possibility of receiving two awards during the course of study.

·$1,000 for Baccalaureate degrees with the possibility of receiving four awards during the course of study.

·$750 for an Associates degree, limited to two awards per applicant.

·$500 for certificate programmes lasting for one year or longer, limited to two awards per applicant.

·$250 for six-month certificate programmes or vocational training programmes, limited to two awards per applicant.

The application deadline is February 15, 2018.

 

More information: CAF announcement 

 

 

CooleySAnemia

The Cooley’s Anemia Foundation is accepting applications for medical research grants and fellowships in areas related to thalassaemia. The awards are in 3 categories:

1. Support for Ongoing Clinical Research in Thalassaemia (Deadline: January 15, 2018 for a letter of intent and February 5, 2018 for invited full applications).

The goal of this initiative is to support investigators from all disciplines and backgrounds (MD, RN, PhD, MPH, MSW or other disciplines) with their ongoing clinical projects to address one or more of the following areas impacting patients with thalassaemia, including but not limited to: cardiac issues and iron overload; fertility, pregnancy and family planning; quality of life, psycho-social impact and/or burden of disease. Funding: $40,000 per year.

2. Clinical Trials in Thalassaemia Cell and Gene Therapy (Deadline: February 5, 2018).

This initiative aims to support clinicians and researchers involved with clinical applications of cell and gene therapy as to advance a cure for thalassaemia. Both phase I (safety) and phase II (efficacy) trials are eligible for support. Funding: $60,000 per year.

3. Research Fellowships (Deadline: February 5, 2018).

This initiative accepts applications from junior faculty and postdoctoral fellows involved with basic and translational research towards the understanding and/or treatment of thalassaemia and/or a complication that is related to thalassaemia. The areas of interest include, but are not limited to, studies of globin gene regulation, globin gene transfer and expression, fetal haemoglobin production, haematopoietic stem cell research, bone marrow transplantation, iron chelation and iron overload, endocrine and cardiac disorders in thalassaemia, and transfusion therapy and its complications.

More information: CAF announcement

Biol. of Blood and Marrow Transpl

 

 

 

 

 

Allogeneic haematopoietic stem cell transplantation (HSCT) is the only established curative therapy for β-thalassaemia. Patients who opt for this treatment are faced with potential late effects that may lead to chronic health conditions. Long-term follow-up after HSCT has the potential to identify late complications of HSCT, allowing for implementation of standardized surveillance strategies and interventions to optimize outcomes and further increase survival rates. While long-term outcomes of HSCT for β-thalassaemia have been reported in literature, these are scarce and limited to single center experiences. An article published in the June 13 issue of the Biology of Blood and Marrow Transplantationreports late effects and long-term health among 176 pediatric patients affected by β-thalassaemia who survived 1 year and beyond after HSCT with a median follow-up of 7 years. This is an original report on long-term follow-up after HSCT for β-thalassaemia using data from multiple international transplant centres. Outcomes of interest included engraftment, chimerism, graft rejection, graft-vs-host disease, ferritin, growth velocity and measures of organ function. Although the study reported high survival among transplant recipients, late organ toxicity and growth impairment was frequently described in those greater than 7 years of age. The incidence of late effects highlighted the need of uniform, careful and systematic follow-up care as to correctly identify and promptly treat any complications that may arise after HSCT. The study also highlighted the need to systematically document the long-term outcomes of HSCT in data registries in order to optimize the tracking and management of post-HSCT health among transplant survivors.

More information:  Publication

fda logo

The U.S. Food and Drug Administration (FDA) approved Endari [PDUFA date: July 7, 2017] for the treatment of sickle cell disease (SCD). This marks a significant milestone in the field as Endari is the first and only FDA-approved treatment for pediatric patients and the first treatment in almost 20 years for adult patients. FDA approval was based on safety and efficacy data from a randomized, double-bind, placebo-controlled multi-centre clinical trial [NCT01179217] involving 230 adult and pediatric patients (5 to 58 years of age). Endari treatment improved the course of SCD, resulting in fewer sickle cell crises and hospitalizations, as well as a lower incidence of the life-threatening acute-chest syndrome. No major adverse events related to treatment were reported.

Endari is an orally-administered pharmaceutical grade L-glutamine made by Emmaus Life Sciences Inc. (Torrance, Calif.). It has received Orphan Drug designation in the U.S., Orphan Medicinal Product designation in the EU and Fast Track designation from the FDA.

 

More information: Press announcement

Page 1 of 16